NOVUS THERAPEUTICS INC's ticker is NVUS and the CUSIP is 67011N105. A total of 17 filers reported holding NOVUS THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $421,000 | -78.8% | 90,199 | -68.2% | 0.26% | -62.9% |
| Q2 2018 | $1,984,000 | +16.2% | 283,383 | -16.4% | 0.71% | +28.4% |
| Q1 2018 | $1,708,000 | +24.1% | 338,929 | 0.0% | 0.55% | +19.8% |
| Q4 2017 | $1,376,000 | +57.6% | 338,929 | +102.3% | 0.46% | +36.2% |
| Q3 2017 | $873,000 | +266.8% | 167,577 | +311.1% | 0.34% | +251.0% |
| Q2 2017 | $238,000 | – | 40,766 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,537,110 | $4,059,000 | 0.08% |
| Boxer Capital, LLC | 324,383 | $519,000 | 0.06% |
| B. Riley Wealth Advisors, Inc. | 120,219 | $193,000 | 0.03% |
| CARY STREET PARTNERS INVESTMENT ADVISORY LLC | 10,600 | $22,000 | 0.02% |
| Sequoia Financial Advisors, LLC | 22,500 | $36,000 | 0.00% |
| VANGUARD GROUP INC | 42,403 | $68,000 | 0.00% |
| RAYMOND JAMES & ASSOCIATES | 10,944 | $18,000 | 0.00% |
| UBS Group AG | 1,061 | $2,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 23,424 | $36,000 | 0.00% |